News

These designations are in addition to the SGN-35 orphan drug designation for Hodgkin lymphoma previously received from the FDA. The company plans to initiate a pivotal trial of

In addition to the 24 countries where SenoRx products are already being sold, the company will begin marketing EnCor, its vacuum-assisted breast biopsy product, and its GelMark line

Sales in local currencies increased by 12% in 2008 and by 9% in Danish kroner. Sales of modern insulins increased by 28% (24% in Danish kroner). Sales of

The Global Initiatives for Proliferation Prevention (GIPP) program under Department of Energy’s National Nuclear Security Administration (NNSA) and AMIC will each contribute $760,000 to the project. The new

The commercial operations and product distribution rights to be acquired by GSK represent approximately 3-4% of UCB’s 2008 expected revenue of at least E3.3 billion. Further details of

The proposed Phase I study is a multi-center, open label, dose escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP in patients with advanced

The company has reported net sales of $3.13 billion for the fourth quarter of 2008, an increase of 4%, compared to $3 billion posted in the fourth quarter

Genpharm has also received final FDA approval for its abbreviated new drug application (ANDA) for a separate lamotrigine product, lamotrigine tablets chewable dispersible (CD). Mylan Pharmaceuticals’s and Genpharm’s

The company reported GAAP earnings per share from continuing operations of $0.29. On a non-GAAP basis, which includes the adjustments noted in the attached reconciliation, the company announced